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ANSWERS
1. Diagnosis: large cell non-Hodgkin lymphoma (NHL) of the
liver.
Differential diagnosis in this patient includes: Kaposi’s
sarcoma (KS), NHL, bacterial (including mycobacterial) absces-
ses, fungal abscesses, amoebiasis and liver metastases or hepa-
toma [1].
In a homosexual man presenting with multiple lesions in the
liver, a diagnosis of Kaposi’s sarcoma should be suspected.
However, the fact that our patient did not present KS lesions
on the skin or KS lesions in other organs is an argument against
such a diagnosis. Furthermore, two different ultrasonic patterns
of KS in the liver are reported: a nodular pattern with small,
hyperechoic nodules scattered close to the portal branches, and
an infiltrative pattern, with thickened and hyperechoic peri-
portal connective tissue [2,3]. The ultrasonic aspects of the
lesions of our patient were hypoechoic. Bacterial (including
mycobacterial) and fungal abscesses of the liver in persons with
HIV infection are not considered as frequent complications,
certainly not in European patients with HIV infection. When
such abscesses occur, they are generally the consequence of an
intra-abdominal infection or a surgical intervention (bacterial
abscesses) or associated with a disseminated infection (myco-
bacterial and fungal abscesses). Liver amoebiasis is also not
known to occur with increased frequency in patients with
HIV infection. Moreover, the patient never resided in a country
where amoebiasis is endemic. In persons without HIV infec-
tion, a negative serologic test for amoebiasis is a strong argument
against liver abscesses caused by amoebiasis. However, in per-
sons with HIV infection, it is known that serologic tests have a
lower predictive value (because of abnormally functioning B-
lymphocytes). Liver metastases should always be excluded even
when there are no clinical arguments that the patient has cancer.
A hepatoma is unlikely in the absence of chronic hepatitis B or
C infection or alcoholic liver disease.
Clinically, the most likely diagnosis is NHL. The treatment of
persons with HIV infection with highly active antiretroviral
treatment (HAART) resulted in a sharp decrease in the incidence
of opportunistic infections [4]. A similar decrease in systemic
NHL, however, has not been observed [4], only a decrease in
the incidence of primary central nervous system lymphoma [5].
Large cell NHL is a well known complication of HIV infection.
It generally occurs when the CD4þ lymphocyte count is below
200 109/L. Only Burkitt’s lymphoma (small cell NHL) may
occur earlier. Hepatic involvement is common in patients with
advanced NHL; over 50% of patients with known systemic
lymphomas show liver involvement at autopsy [6]. Hepatic
NHL in patients with AIDS usually presents with multiple large
hepatic masses and involvement of other abdominal organs or
lymph nodes [7]. NHL localized only in the liver in patients
with HIV infection is exceptional [8–12]. Most of these cases
present with multiple hypodense mass lesions larger than those
seen with opportunistic infections or Kaposi’s sarcoma [13].
2. The diagnosis of NHL was made by histologic examina-
tion of a liver biopsy. Cultures of liver tissue did not grow any
organism. No other localizations of lymphoma were found on
CT scan and bone marrow biopsy. This patient had a relatively
high CD4þ lymphocyte count at the time when the NHL was
diagnosed. It is, however, likely that the NHL was already
present earlier before the HAARTwas started, when his CD4þ
lymphocyte count was below 100 109/L.
3. NHL in persons with HIV infection should be treated in a
similar way as in non-HIV-infected individuals [14]. Our
patient received cyclophosphamide, doxorubicin, vincristine
and prednisone (CHOP). A problem in persons with HIV
infection is how to combine HAART with chemotherapy. It
is advisable to treat patients concomitantly with chemotherapy
and HAART, but to choose antiretrovirals that do not increase
the potential toxicity of the chemotherapy [14]. For example,
zidovudine is contraindicated because of its hematoxicity.
Administering stavudine and didanosine may increase the
potential neurotoxicity of vincristine [15]. Certain patients
may not tolerate HAART regimens during chemotherapy
because of gastrointestinal problems/side-effects.
In our patient, we were able to continue HAART, but the
stavudine was switched to nevirapine. During chemotherapy,
his clinical condition rapidly improved. Now, 1 year later, he is
in good health. His CD4þ lymphocyte count is 214 109/L,
his viral load is undetectable (below 50 copies/mL plasma) and
ultrasound examination of the abdomen no longer shows focal
liver lesions.
HAART has considerably improved the prognosis of patients
with HIV infection [16]. It is therefore becoming increasingly
important to detect infectious and malignant complications as
early as possible in order to treat these conditions in an optimal
way.
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Clinicalmicrobiological case: refractory chest wall infection
following reconstructive surgery in a patient with relapsed
lung cancer
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CLINICAL OUTCOME
Ten weeks following the start of empirical therapy for Myco-
bacterium tuberculosis (isoniazid 300 mg, rifampin 600 mg,
ethambutol 1200 mg and pyrizinamide 1500 mg daily), the
patient’s symptoms progressed. A second chest wall exploration,
including extensive debridement and removal of the infected
prolene mesh, was performed 12 weeks later. Fibroadipose
tissue, breast and skeletal muscle specimens revealed acute
and chronic (dimorphic) inflammation, with foreign body giant
cell reaction. Acid-fast bacilli and granuloma were conspicu-
ously absent, and the chest wound was left to heal by secondary
intention (Figure 2).
Three weeks after surgery, M. fortuitum and M. abscessus were
isolated from all surgical specimens. Treatment was changed to
oral ciprofloxacin (500 mg) and clarithromycin (500 mg) twice
daily and continued for 6 months. The chest wound healed
completely, and mastitis resolved (Figure 3). No recurrence was
reported on 18-month follow-up.
DIAGNOSIS
M. fortuitum and M. abscessus prosthetic device infection.
DISCUSSION
1. Infections due to the rapidly growing mycobacteria (RGM)
have emerged as an important cause of morbidity and mortality
for humans, and are often seen in patients following penetrating
trauma and reconstructive surgery [1–3].M.chelonae,M.fortuitum
Figure 2 The left anterio-lateral chest wall wound following surgical debri-
dement and prolene mesh removal.
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